Skip to content

Upstream Bio, Inc. UPB Investing Cash Flow

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$716M-60.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$30.93M-262%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$23.85M+52.9%
Savara logo
SavaraSVRA
$38.78M+32.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$34.98M+136%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s investing cash flow?
Upstream Bio, Inc. (UPB) reported investing cash flow of $42.4M in Q1 2026.
How has Upstream Bio, Inc.'s investing cash flow changed year-over-year?
Upstream Bio, Inc.'s investing cash flow increased by 119.9% year-over-year, from -$213.38M to $42.4M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.